Literature DB >> 11704782

Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.

R L Barkin1.   

Abstract

Pain of multiple etiologies remains a substantial problem for many patients presenting in the clinical setting. Improved pain relief can be demonstrated, and adverse effects minimized, by multimodal analgesic combinations as the method to improve pain treatment. Substantial evidence supports combining analgesics for the management of pain and, in some instances, they have a heterogeneous pharmacologic sparing effect. Fixed-dose combination analgesics with demonstrated efficacy and safety are widely useful for pain management. However, work needs to continue to further explore which analgesics at which doses can be combined with a coanalgesic in a patient-specific manner to achieve additive, if not synergistic, multimodal pain relief with the fewest possible adverse consequences. Unsupervised consumption of over-the-counter drugs that contain acetaminophen, aspirin, or ibuprofen offers clinical challenges to both the patient and health care providers. Couple this often undisclosed over-the-counter medication consumption event with prescription medications, which many contain similar combination ingredients, and the potential for a therapeutic misadventure may precipitate. This article will address the safety and efficacy of acetaminophen, aspirin, and ibuprofen independently and in combination with currently available prescription dosage forms with a focus on pharmacology, pharmacotherapeutics, pharmacodynamics, and pharmacokinetics, including drug interactions at the CYP450 system. Patient-specific cautions are presented for opiate/opioid combinations, codeine, hydrocodone, oxycodone, and propoxyphene, and there is a discussion of COX I/COX II agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704782     DOI: 10.1097/00045391-200111000-00008

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  17 in total

1.  Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.

Authors:  Mona Darwish; Mary Bond; William Tracewell; Philmore Robertson; Ronghua Yang
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 2.859

Review 2.  Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain.

Authors:  Antonio Gatti; Elisabetta Sabato; Anna Rita Di Paolo; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology.

Authors:  Mona Darwish; Ronghua Yang; William Tracewell; Philmore Robertson; Mary Bond
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

4.  Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.

Authors:  Mary Bond; Laura Rabinovich-Guilatt; Sally Selim; Mona Darwish; William Tracewell; Philmore Robertson; Ronghua Yang; Richard Malamut; Philippe Colucci; Murray P Ducharme; Ofer Spiegelstein
Journal:  Clin Drug Investig       Date:  2017-12       Impact factor: 2.859

Review 5.  An Approach to Drug-Induced Liver Injury from the Geriatric Perspective.

Authors:  Brian T Lee; Joseph A Odin; Priya Grewal
Journal:  Curr Gastroenterol Rep       Date:  2021-04-12

Review 6.  Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain.

Authors:  Vicki Oldfield; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Utilization and effectiveness of multimodal discharge analgesia for postoperative pain management.

Authors:  Karishma Desai; Ian Carroll; Steven M Asch; Tina Seto; Kathryn M McDonald; Catherine Curtin; Tina Hernandez-Boussard
Journal:  J Surg Res       Date:  2018-04-11       Impact factor: 2.192

Review 8.  The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.

Authors:  Thomas M Tzschentke; Thomas Christoph; Babette Y Kögel
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

9.  De facto long-term opioid therapy for noncancer pain.

Authors:  Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Clin J Pain       Date:  2008 Jul-Aug       Impact factor: 3.442

10.  Knowledge of drug prescription in dentistry students.

Authors:  R Guzmán-Álvarez; M Medeiros; Li Reyes Lagunes; Ae Campos-Sepúlveda
Journal:  Drug Healthc Patient Saf       Date:  2012-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.